logo
Plus   Neg
Share
Email

Merck, Pfizer: FDA Approves Steglatro And Fixed-dose Combination Steglujan

Merck & Co. Inc. (MRK) and Pfizer Inc. (PFE) said that the U.S. Food and Drug Administration has approved Steglatro (ertugliflozin) tablets, an oral sodium-glucose cotransporter 2 or SGLT2 inhibitor, and the fixed-dose combination Steglujan (ertugliflozin and sitagliptin) tablets.

Steglatro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate.

Steglatro and Steglujan are not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Steglujan has not been studied in patients with a history of pancreatitis and it is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Steglujan.

Steglatro and Steglujan are contraindicated in patients with severe renal impairment, end-stage renal disease or on dialysis, or with a history of a serious hypersensitivity reaction to ertugliflozin. Steglujan is also contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin (such as anaphylaxis or angioedema).

These FDA approvals are supported by seven Phase 3 studies of approximately 4,800 patients. Steglatro was studied as monotherapy and in combination with metformin and/or sitagliptin, as well as with insulin and a sulfonylurea, in adults with type 2 diabetes and moderate renal impairment.

Diabetes is a chronic, progressive disease affecting approximately 30 million Americans. About one-third of adults with type 2 diabetes in the U.S. are not at their A1C goal.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Down the line, GE has transformed from a too-big-to-fail conglomerate to a too-big-for-success albatross. The company has admitted to being too-much focused on EPS and operating profit, and not paying enough attention to cash. However, GE is certainly learning lessons from its past and refocusing its strategies to stage a comeback to its Camelot days, the key catalysts being... Industrial conglomerate General Electric Co., one of the original components of the Dow Jones Industrial Average, has been replaced by Walgreens Boots Alliance Inc. in the blue-chip index. The change comes into effect prior to the open of trading on Tuesday, June 26. The 122-year-old Dow Jones Industrial Average, or simply the Dow, is a stock market index with 30 component companies. A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019.
Follow RTT